PREVENT-2024
Financiado
MOVING FROM BIOMARKERS TO MECHANISM ORIENTED PREVENTION OF CARDIOMETABOLIC DISEA...
Increasing occurrence of obesity and diabetes is the major threat to cardiovascular health of our century. Whereas the field is saturated with omics strategies aimed at improving prediction of cardiometabolic disease (CMD), mechan...
Increasing occurrence of obesity and diabetes is the major threat to cardiovascular health of our century. Whereas the field is saturated with omics strategies aimed at improving prediction of cardiometabolic disease (CMD), mechanism-orientated prevention strategies, which is what the population calls for, are lacking. We here propose three completely new and high-risk strategies to prevent CMD in large subsets of the population, who have elevated risk due to measurable endocrine abnormalities.
SUBPROJECT 1: We test if the increased CMD risk linked to high levels of the intestinal fat absorption and storage promoting hormone neurotensin (NTS), can be improved by: (A) blockade of NTS using monoclonal antibodies in mice and (B) inhibition of NTS secretion and intestinal fat uptake with the drug orlistat in humans.
SUBPROJECT 2: High plasma levels of vasopressin (VP) (present in 25% of the population) is a strong risk factor for later CMD and the dominating cause of high VP is low water intake. We therefore test if the elevated CMD risk in subjects with high VP can be reduced by increasing water intake in a large 12-month randomized trial of 1.5 L water supplementation vs control therapy.
SUBPROJECT 3: Aderenomedullin (ADM), whose endothelial secretion is enhanced in obesity, has beneficial effects on the intravascular wall but in the extravascular space, to which it diffuses freely, it may promote diabetes. We investigate how long-term increase and decrease of levels of bioactive ADM in the intra- and extravascular compartments, respectively, affect atherosclerosis and glucose metabolism in mice. In humans we test if a monoclonal antibody, which traps ADM in the circulation (while still allowing it to bind to its endothelial receptors) and drains it from the extravascular space, improves vascular function and glucose metabolism.
We provide completely novel, mechanism-orientated and near-future applicable strategies for primary prevention of CMD.
ver más
Duración del proyecto: 61 meses
Fecha Inicio: 2020-11-18
Fecha Fin: 2025-12-31
Fecha Fin: 2025-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-11-18
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-ADG:
ERC Advanced Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
LUNDS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
923.86K€ |
Participante